Investigation on Safety, Tolerability and Pharmacokinetics of Single Doses of NNC0174-0833 in Normal Weight, Overweight to Obese But Otherwise Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 03 Aug 2017
At a glance
- Drugs NNC 0174 0833 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 07 Apr 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Mar 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 02 Dec 2015 Time frame for primary endpoint changed from day 29-36 to day 43-50. Patient population altered:- normal weight subjects also included. Treatment altered:- 9 doses being tested instead of 7 as per ClinicalTrials.gov record